Get the Stockscreener App
9.34
0.86%
0.08
After Hours:
9.35
0.010
+0.11%
Novavax Inc stock is traded at $9.34, with a volume of 2.70M.
It is up +0.86% in the last 24 hours and down -1.99% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$9.26
Open:
$9.39
24h Volume:
2.70M
Relative Volume:
0.54
Market Cap:
$1.52B
Revenue:
$1.12B
Net Income/Loss:
$440.30M
P/E Ratio:
3.9235
EPS:
2.3805
Net Cash Flow:
$-251.02M
1W Performance:
-6.69%
1M Performance:
-1.99%
6M Performance:
+11.99%
1Y Performance:
+23.54%
1-Day Range:
$9.22
$9.60
1-Week Range:
$9.22
$10.00
52-Week Range:
$5.01
$11.97
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.34 | 1.51B | 1.12B | 440.30M | -251.02M | 2.3805 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NVAX SEC FilingsNovavax Inc 10-K, 10-Q, 8-K Forms - Stock Titan
(NVAX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Novavax Inc. stock rises Monday, still underperforms market - MarketWatch
Novavax Q2 2025 Earnings Preview - MSN
Wall Street Recap: Can Novavax Inc stock outperform in a bear marketTrade Entry Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 Earnings Estimate for Novavax Issued By Zacks Research - MarketBeat
2 Healthcare Stocks to Target This Week and 1 That Underwhelm - The Globe and Mail
Assessing Novavax (NVAX) Valuation As Licensing Income And COVID Momentum Shape Expectations - Yahoo Finance
Aug Selloffs: Is Novavax Inc benefiting from interest rate changesMarket Growth Report & Entry and Exit Point Strategies - baoquankhu1.vn
NVAX stock rises overnight ahead of Q4 print with Pfizer tailwinds — analyst warns of 20% crash - MSN
Novavax (NVAX) Shares Drop 1.23%: Key Information to Note - Bitget
Novavax (NVAX) Stock Moves -1.23%: What You Should Know - Yahoo! Finance Canada
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Therapeutics Sector Q4 Results: Revenue Beats Amid Market Stability - IndexBox
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is trending stock Novavax, Inc. (NVAX) a buy now? - MSN
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NASDAQ:NVAX) Trading 7.6% HigherShould You Buy? - MarketBeat
Here’s What You Should Understand Besides the Reason Novavax, Inc. (NVAX) is Gaining Attention - Bitget
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance
DC InnoNovavax cancels Covid-19 vaccine contract | Oxiwear is going global - The Business Journals
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Farallon Capital Management LLC Purchases 764,000 Shares of Novavax, Inc. $NVAX - MarketBeat
Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - Yahoo Finance
How (NVAX) Movements Inform Risk Allocation Models - Stock Traders Daily
FDA to Mandate Placebo-Controlled Trials for New Vaccines - MSN
Jefferies Maintains Buy on Novavax, Inc. (NVAX) March 2026 - Meyka
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT - MSN
Novavax (NVAX) director John W. Shiver converts 7,947 RSUs into stock - Stock Titan
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform By Investing.com - Investing.com India
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform - Investing.com
Assessing Novavax (NVAX) Valuation After Strong 2025 Results And Return To Profitability - simplywall.st
Novavax (NASDAQ:NVAX) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Novavax Q4 earnings preview: Wall Street expects wider losses amid diversification efforts - MSN
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement - MSN
Novavax stock hits over 1-year high: Is Sanofi’s flu-COVID shot the post-pandemic growth driver? - MSN
The 7 Most Hated Stocks on Wall Street Today | Investing - Money/ US News
NVAX: Pivot to platform partnerships and innovation drives growth, with profitability targeted by 2028 - TradingView
Novavax (NVAX) EVP granted 139,500 non-statutory stock options - Stock Titan
Novavax Inc. (NVAX) legal chief updates 152,000-share stock option terms - Stock Titan
Novavax (NVAX) EVP granted 177,500 options with revised terms - Stock Titan
Therapeutics Companies Exceed Q4 2025 Revenue Estimates, Led by Novavax and AmgenNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Novavax (NVAX) CEO updates exercise price on 551,500 stock options - Stock Titan
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling - MSN
NOVAVAX INC (NASDAQ:NVAX) Screens as a Minervini-Style High-Growth Momentum Candidate - ChartMill
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):